Literature DB >> 24634490

Tissue requirements for establishing long-term CD4+ T cell-mediated immunity following Leishmania donovani infection.

Patrick T Bunn1, Amanda C Stanley, Fabian de Labastida Rivera, Alexander Mulherin, Meru Sheel, Clare E Alexander, Rebecca J Faleiro, Fiona H Amante, Marcela Montes De Oca, Shannon E Best, Kylie R James, Paul M Kaye, Ashraful Haque, Christian R Engwerda.   

Abstract

Organ-specific immunity is a feature of many infectious diseases, including visceral leishmaniasis caused by Leishmania donovani. Experimental visceral leishmaniasis in genetically susceptible mice is characterized by an acute, resolving infection in the liver and chronic infection in the spleen. CD4+ T cell responses are critical for the establishment and maintenance of hepatic immunity in this disease model, but their role in chronically infected spleens remains unclear. In this study, we show that dendritic cells are critical for CD4+ T cell activation and expansion in all tissue sites examined. We found that FTY720-mediated blockade of T cell trafficking early in infection prevented Ag-specific CD4+ T cells from appearing in lymph nodes, but not the spleen and liver, suggesting that early CD4+ T cell priming does not occur in liver-draining lymph nodes. Extended treatment with FTY720 over the first month of infection increased parasite burdens, although this associated with blockade of lymphocyte egress from secondary lymphoid tissue, as well as with more generalized splenic lymphopenia. Importantly, we demonstrate that CD4+ T cells are required for the establishment and maintenance of antiparasitic immunity in the liver, as well as for immune surveillance and suppression of parasite outgrowth in chronically infected spleens. Finally, although early CD4+ T cell priming appeared to occur most effectively in the spleen, we unexpectedly revealed that protective CD4+ T cell-mediated hepatic immunity could be generated in the complete absence of all secondary lymphoid tissues.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24634490     DOI: 10.4049/jimmunol.1300768

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum.

Authors:  Audrey Romano; Nicole A Doria; Jonatan Mendez; David L Sacks; Nathan C Peters
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

2.  Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential.

Authors:  Shashi Bhushan Chauhan; Rebecca Faleiro; Rajiv Kumar; Susanna Ng; Bhawana Singh; Om Prakash Singh; Siddharth Sankar Singh; Fiona Amante; Fabian de Labastida Rivera; Madhukar Rai; Jaya Chakravarty; David Sacks; Susanne Nylen; Shyam Sundar; Christian Engwerda
Journal:  J Infect Dis       Date:  2019-06-05       Impact factor: 5.226

3.  Combined Immune Therapy for the Treatment of Visceral Leishmaniasis.

Authors:  Rebecca J Faleiro; Rajiv Kumar; Patrick T Bunn; Neetu Singh; Shashi Bhushan Chauhan; Meru Sheel; Fiona H Amante; Marcela Montes de Oca; Chelsea L Edwards; Susanna S Ng; Shannon E Best; Ashraful Haque; Lynette Beattie; Louise M Hafner; David Sacks; Susanne Nylen; Shyam Sundar; Christian R Engwerda
Journal:  PLoS Negl Trop Dis       Date:  2016-02-12

Review 4.  Modulation of Innate Immune Mechanisms to Enhance Leishmania Vaccine-Induced Immunity: Role of Coinhibitory Molecules.

Authors:  Sreenivas Gannavaram; Parna Bhattacharya; Nevien Ismail; Amit Kaul; Rakesh Singh; Hira L Nakhasi
Journal:  Front Immunol       Date:  2016-05-13       Impact factor: 7.561

5.  Visceral leishmaniasis complicating idiopathic CD4+ T-cell lymphocytopenia: 2 case reports.

Authors:  Andrew Fox-Lewis; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2017-05-11

Review 6.  Lessons from other diseases: granulomatous inflammation in leishmaniasis.

Authors:  Paul M Kaye; Lynette Beattie
Journal:  Semin Immunopathol       Date:  2015-12-17       Impact factor: 9.623

Review 7.  Post-Genomics and Vaccine Improvement for Leishmania.

Authors:  Negar Seyed; Tahereh Taheri; Sima Rafati
Journal:  Front Microbiol       Date:  2016-04-06       Impact factor: 5.640

Review 8.  Regulation of immunity during visceral Leishmania infection.

Authors:  Vasco Rodrigues; Anabela Cordeiro-da-Silva; Mireille Laforge; Ricardo Silvestre; Jérôme Estaquier
Journal:  Parasit Vectors       Date:  2016-03-01       Impact factor: 3.876

9.  Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.

Authors:  Elisangela Oliveira Freitas; Dirlei Nico; Marcus Vinícius Alves-Silva; Alexandre Morrot; Keith Clinch; Gary B Evans; Peter C Tyler; Vern L Schramm; Clarisa B Palatnik-de-Sousa
Journal:  PLoS Negl Trop Dis       Date:  2015-12-23

10.  Galectin-1 Impairs the Generation of Anti-Parasitic Th1 Cell Responses in the Liver during Experimental Visceral Leishmaniasis.

Authors:  Patrick T Bunn; Marcela Montes de Oca; Fabian de Labastida Rivera; Rajiv Kumar; Chelsea L Edwards; Rebecca J Faleiro; Susanna S Ng; Meru Sheel; Yulin Wang; Fiona H Amante; Ashraful Haque; Christian R Engwerda
Journal:  Front Immunol       Date:  2017-10-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.